Uridine triacetate, is an orally bioavailable prodrug of uridine, which is efficiently absorbed and rapidly converted to circulating uridine by deacetylation. The uridine is then converted to UTP, which competes with FUTP for incorporation into RNA, thereby preventing cell death.
Uridine triacetate is supplied in sachets containing 10g uridine triacetate as an orange-flavoured powder sprinkle for food. Patients receive 10g every 6 hours for 20 doses. Treatment must start as soon as possible, but within 96 hours of the overdose.
This product is available from Wellstat Therapeutics Corporation.
Contact Person:
Bob Tremmel, B.S. Pharmacy, PharmD, RPh
Clinical Safety Manager
Wellstat Therapeutics Corporation
930 Clopper Road
Gaithersburg, MD 20878
Office: 240-631-2500 ext. 3238
Fax: 240-465-1144
Email: rtremmel@Wellstat.com
All clinicians must provide Wellstat with all clinical documents related to the overdose and patient. This information will be used to form a submission report in an application for marketing authorisation (likely to go ahead in the next year or so).
There is no charge for the product, but shipping costs are expensive. The shipping charge from DHL was quoted as approximately $16,500 (USD) from the US to New
Zealand and delivery to Waikato Hospital in June 2012.
Maxine Handford
18/06/2013